The FDA Just Suspended Milk Quality Testing for Avian Flu and Other Viruses
Consumers look to the Food and Drug Administration (FDA) for guidance and oversight regarding a number of issues, including food safety. However, recent staff reductions and budget cuts have sparked discussion about the agency's ability to fulfill its mission as it continues to operate at a reduced capacity.
As talk of additional reductions looms, it has been revealed that a FDA program that tests milk quality has now been suspended.
On April 21, the FDA suspended one of its programs that oversees the safety of dairy products nationwide. This week, Reuters reported on an internal email addressed to "Network Laboratories" from the FDA's Division on Dairy Safety stating that the Moffett Center Proficiency Testing Laboratory is "no longer able to provide proficiency testing and data analysis."
This change is due to reduced capacity in its food safety and nutrition division. The suspension includes quality testing for Grade "A" milk, which has the highest sanitary standards, and includes both raw milk and finished products, such as pasteurized milk and cheese.
This news comes after it was announced earlier this month that the FDA would also be suspending the programs that oversee testing accuracy regarding avian flu in milk, as well as parasites such as Cyclospora, which can affect raw milk. It is believed that the suspensions are the result of staff shortages after nearly 20,000 U.S Department of Health and Human Services (HHS) employees were terminated in March.
It's unclear what, if any, effects the disruption will have on consumers. However, the pause is expected to be temporary. Emily Hiliard, Deputy Press Secretary for HHS, told Allrecipes in a statement that testing is expected to continue once the department's transition is completed.
"The Food Emergency Response Network Proficiency Testing Program is currently paused but will resume once transferred to another FDA laboratory—an effort that is actively underway," Hiliard continues, "In the meantime, state and federal labs continue to analyze food samples, and FDA remains committed to working with states to protect the safety of the pasteurized milk supply."
At present, no official timeline has been given regarding the program's resumption.
The FDA says it will continue to work with state and federal labs to ensure food safety. Additionally, prior FDA research has shown that pasteurization is effective in killing the H5N1 (Avian flu) virus, and the Centers for Disease Control (CDC) states that "consuming raw milk can lead to serious health risks, especially for certain vulnerable populations."
Consumers can additionally seek brands that utilize independent, third-party testing. Some milk brands have their products evaluated by third parties to ensure they meet safety standards and are free from viruses and bacteria, even beyond what state and federal guidelines require. This information is typically available on the brand's website, but if you can't find it, don't hesitate to reach out to the company for more information on its internal testing practices. A USDA Organic certification does not necessarily mean a product is safer or that it has undergone additional food safety testing.
In the meantime, it's also crucial to stay up to date on recalls and public health alerts on the FDA and USDA websites.
Read the original article on ALLRECIPES
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
3 hours ago
- Business Insider
Argenx presents new Efgartigimod data at EULAR 2025
argenx (ARGX) SE 'announced the presentation of positive results from Phase 2 studies evaluating VYVGART in Sjogren's disease and idiopathic inflammatory myopathies at the European Congress of Rheumatology, EULAR 2025, from June 11 – 14 in Barcelona, Spain. argenx also announced that the FDA has granted efgartigimod Fast Track designation for the treatment of primary Sjogren's disease.' Confident Investing Starts Here: Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
3 hours ago
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
5 hours ago
- Yahoo
Iowa HHS reports second case of measles in state this year
DES MOINES, Iowa — Iowa Health and Human Services is reporting that a second confirmed case of measles has been detected in Iowa this year. According to the Iowa HHS website, the second case was confirmed in a vaccinated adult male between the ages of 18 to 40 in eastern Iowa in June. It is unknown at this time whether the patient traveled outside of the state. Iowa DNR reporting fish kill at Des Moines lake In May HHS announced the first confirmed case of measles in the state since 2019. The infected individual was an unvaccinated adult female and had traveled outside of the state and internationally. The announcement comes as the highly contagious disease continues to spread across the country, with 34 states reporting cases. According to the CDC, over 1,100 cases have been reported in the country as of June 5, a majority of them occurring in Texas. Measles is a highly contagious and potentially deadly disease. It spreads through the air when a person infected with the virus coughs or sneezes. Symptoms appear roughly 7-21 days after infection and include: cough, red and/or watery eyes, nasal congestion, fever, rash, and Koplik spots. If you believe you've been exposed to measles or may have measles HHS says to call your healthcare provider as soon as possible. Iowa News: Hot, muggy Wednesday and storm chances Iowa HHS reports second case of measles in state this year Increase in ATV/UTV popularity brings more crashes on roads Dozens of dogs rescued from 'neglectful conditions' at eastern Iowa breeder nearly 2 years after first rescue Satanic Temple accuses Iowa officials of religious discrimination Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.